Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 476

1.

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Zanger UM, Raimundo S, Eichelbaum M.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. Epub 2003 Nov 15. Review.

PMID:
14618296
2.

Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.

Neafsey P, Ginsberg G, Hattis D, Sonawane B.

J Toxicol Environ Health B Crit Rev. 2009;12(5-6):334-61. doi: 10.1080/10937400903158342. Review.

PMID:
20183526
3.

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.

Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T, Eichelbaum M.

Pharmacogenetics. 1998 Feb;8(1):15-26.

PMID:
9511177
4.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Zhou SF.

Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review.

PMID:
19817501
5.

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Sachse C, Brockmöller J, Bauer S, Roots I.

Am J Hum Genet. 1997 Feb;60(2):284-95.

6.

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M.

Pharmacogenetics. 2001 Oct;11(7):573-85.

PMID:
11668217
7.
8.

Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.

Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.

Pharmacogenetics. 1999 Dec;9(6):715-23.

PMID:
10634134
9.

Cytochrome P450 CYP2D6.

Wolf CR, Smith G.

IARC Sci Publ. 1999;(148):209-29. Review.

PMID:
10493260
10.

Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.

Yu AM, Idle JR, Gonzalez FJ.

Drug Metab Rev. 2004 May;36(2):243-77. Review.

PMID:
15237854
11.

Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.

Isaza CA, Henao J, López AM, Cacabelos R.

Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):695-705.

PMID:
11294012
12.

Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6.

Kitada M.

Int J Clin Pharmacol Res. 2003;23(1):31-5. Review.

PMID:
14621071
14.

The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Thuerauf N, Lunkenheimer J.

Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):287-93. Review.

PMID:
16783493
15.

Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.

Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A.

Biotechniques. 2005 Oct;39(4):571-4.

16.

[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].

Szewczuk-Bogusławska M, Grzesiak M, Beszłej JA, Kiejna A.

Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104. Review. Polish.

PMID:
15779673
17.
18.
20.

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML.

Psychopharmacology (Berl). 1999 Dec;147(3):300-5.

PMID:
10639689

Supplemental Content

Support Center